Kane LP[au] - Search Results

Year	Number of Results
1990	1
1991	2
1992	1
1993	3
1994	1
1996	2
1998	1
1999	1
2000	3
2001	2
2002	3
2003	1
2004	3
2005	2
2006	3
2007	2
2008	3
2009	2
2010	4
2011	6
2012	2
2013	3
2014	6
2015	3
2016	6
2017	11
2018	6
2019	3
2020	6
2021	2

1

TIM-3 as a Target for Cancer Immunotherapy and Mechanisms of Action.

Du W, Yang M, Turner A, Xu C, Ferris RL, Huang J, Kane LP, Lu B. Du W, et al. Among authors: kane lp. Int J Mol Sci. 2017 Mar 16;18(3):645. doi: 10.3390/ijms18030645. Int J Mol Sci. 2017. PMID: 28300768 Free PMC article. Review.

2

Kidney-infiltrating T cells in murine lupus nephritis are metabolically and functionally exhausted.

Tilstra JS, Avery L, Menk AV, Gordon RA, Smita S, Kane LP, Chikina M, Delgoffe GM, Shlomchik MJ. Tilstra JS, et al. Among authors: kane lp. J Clin Invest. 2018 Nov 1;128(11):4884-4897. doi: 10.1172/JCI120859. Epub 2018 Sep 24. J Clin Invest. 2018. PMID: 30130253 Free PMC article.

3

Noncanonical STAT3 activity sustains pathogenic Th17 proliferation and cytokine response to antigen.

Poholek CH, Raphael I, Wu D, Revu S, Rittenhouse N, Uche UU, Majumder S, Kane LP, Poholek AC, McGeachy MJ. Poholek CH, et al. Among authors: kane lp. J Exp Med. 2020 Oct 5;217(10):e20191761. doi: 10.1084/jem.20191761. J Exp Med. 2020. PMID: 32697822 Free PMC article.

4

Immune regulation by Tim-3.

Banerjee H, Kane LP. Banerjee H, et al. Among authors: kane lp. F1000Res. 2018 Mar 14;7:316. doi: 10.12688/f1000research.13446.1. eCollection 2018. F1000Res. 2018. PMID: 29560265 Free PMC article. Review.

5

Novel Effector Phenotype of Tim-3⁺ Regulatory T Cells Leads to Enhanced Suppressive Function in Head and Neck Cancer Patients.

Liu Z, McMichael EL, Shayan G, Li J, Chen K, Srivastava R, Kane LP, Lu B, Ferris RL. Liu Z, et al. Among authors: kane lp. Clin Cancer Res. 2018 Sep 15;24(18):4529-4538. doi: 10.1158/1078-0432.CCR-17-1350. Epub 2018 Apr 30. Clin Cancer Res. 2018. PMID: 29712685 Free PMC article.

6

PD-1/SHP-2 inhibits Tc1/Th1 phenotypic responses and the activation of T cells in the tumor microenvironment.

Li J, Jie HB, Lei Y, Gildener-Leapman N, Trivedi S, Green T, Kane LP, Ferris RL. Li J, et al. Among authors: kane lp. Cancer Res. 2015 Feb 1;75(3):508-518. doi: 10.1158/0008-5472.CAN-14-1215. Epub 2014 Dec 5. Cancer Res. 2015. PMID: 25480946 Free PMC article.

7

Adaptive resistance to anti-PD1 therapy by Tim-3 upregulation is mediated by the PI3K-Akt pathway in head and neck cancer.

Shayan G, Srivastava R, Li J, Schmitt N, Kane LP, Ferris RL. Shayan G, et al. Among authors: kane lp. Oncoimmunology. 2016 Dec 23;6(1):e1261779. doi: 10.1080/2162402X.2016.1261779. eCollection 2017. Oncoimmunology. 2016. PMID: 28197389 Free PMC article.

8

Promotion of tissue inflammation by the immune receptor Tim-3 expressed on innate immune cells.

Anderson AC, Anderson DE, Bregoli L, Hastings WD, Kassam N, Lei C, Chandwaskar R, Karman J, Su EW, Hirashima M, Bruce JN, Kane LP, Kuchroo VK, Hafler DA. Anderson AC, et al. Among authors: kane lp. Science. 2007 Nov 16;318(5853):1141-3. doi: 10.1126/science.1148536. Science. 2007. PMID: 18006747 Free article.

9

Control of T lymphocyte fate decisions by PI3K signaling.

Murter B, Kane LP. Murter B, et al. Among authors: kane lp. F1000Res. 2020 Sep 25;9:F1000 Faculty Rev-1171. doi: 10.12688/f1000research.26928.1. eCollection 2020. F1000Res. 2020. PMID: 33024547 Free PMC article. Review.

10

A predicted Francisella tularensis DXD-motif glycosyltransferase blocks immune activation.

Nau GJ, Horzempa J, O'Dee D, Brown MJ, Russo BC, Hernandez A, Dillon ST, Cheng J, Kane LP, Sanker S, Hukriede NA. Nau GJ, et al. Among authors: kane lp. Virulence. 2019 Dec;10(1):643-656. doi: 10.1080/21505594.2019.1631662. Virulence. 2019. PMID: 31314675 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results